Granted Patent
B2
US 12,239,819 · App. 17/056,387 · Granted Mar 4, 2025
Method and system to treat acute decompensated heart failure
Inventors:
Howard R. Levin (New York, NY); Andrew Halpert (Milford, MA); Zoar Engelman (New York, NY); Mark Gelfand (New York, NY)
Assignee:
Reprieve Cardiovascular, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A apparatus and method to treat patients with acute decompensated heart failure (ADHF), heart failure or another fluid overload condition, that includes: administrating a diuretic to the patient to increase urine output of the patient; monitoring a rate or amount of urine output by the patient after administration of the diuretic; infusing a hydration liquid into the patient to induce an increase in the urine output; and adjusting the rate or amount of the hydration liquid infused into the patient to achieve a target fluid loss in the patient.
Claims (33)
1. A fluid management system, comprising:
a measurement system configured to measure urine output from a patient;
a pump configured to provide hydration fluid to the patient; and
a control system operatively coupled to the measurement system and the pump, the control system being configured to—
obtain a urine output rate based on the measured urine output from the measurement system;
receive a desired net fluid loss rate for the patient;
during a first period, cause the hydration fluid to be provided, via the pump, to the patient at a hydration fluid rate; and
during a second period after the first period, and based on at least one of the urine output rate or the desired net fluid loss rate, adjust operation of the pump to increase the hydration fluid rate.
2. The fluid management system of claim 1 , wherein the control system is further configured to obtain an amount of diuretic or a diuretic dosage rate provided to the patient.
3. The fluid management system of claim 2 , wherein adjusting operation of the pump is further based on the obtained amount of diuretic or diuretic dosage rate.
4. The fluid management system of claim 1 , wherein the control system is further configured to cause a diuretic to be provided to the patient at a diuretic dosage rate.
5. The fluid management system of claim 1 , wherein the control system is further configured to provide an indication that a diuretic dosage rate is to be increased, based on the obtained urine output rate being below a threshold rate.
6. The fluid management system of claim 1 , wherein the control system is further configured to obtain an actual net fluid loss rate based at least in part on the urine output rate and the hydration fluid rate, and wherein adjusting operation of the pump to increase the hydration fluid rate is based on a difference between the desired net fluid loss rate and the actual net fluid loss rate.
7. The fluid management system of claim 1 , wherein the desired net fluid loss rate is at least 50 milliliters/hour.
8. The fluid management system of claim 1 , wherein causing the hydration fluid to be provided to the patient at the hydration fluid rate is based at least in part on the urine output rate relative to a predetermined threshold urine rate or amount.
9. The fluid management system of claim 1 , wherein the control system is further configured to adjust operation of the pump to decrease the hydration fluid rate, based on the obtained urine output rate being above a threshold rate.
10. The fluid management system of claim 1 , wherein adjusting operation of the pump to increase the hydration fluid rate is based on the obtained urine output rate being below a threshold rate.
11. The fluid management system of claim 1 , wherein adjusting operation of the pump to increase the hydration fluid rate is based on both the urine output rate and the desired net fluid loss rate.
12. The fluid management system of claim 1 , further comprising a blood pressure monitor operatively coupled to the control system, wherein the control system is further configured to monitor a blood pressure of the patient, via the blood pressure monitor, while causing the hydration fluid to be provided.
13. The fluid management system of claim 12 , wherein adjusting operation of the pump to increase the hydration fluid rate is further based on the monitored blood pressure.
14. A method for managing fluid levels in a patient, the method comprising:
obtaining a urine output rate from a patient;
receiving a desired net fluid loss rate for the patient;
during a first period, cause the hydration fluid to be provided, via the pump, to the patient at a hydration fluid rate; and
during a second period after the first period, and based on at least one of the urine output rate or the desired net fluid loss rate, adjust operation of the pump to increase the hydration fluid rate.
15. The method of claim 14 , further comprising obtaining an amount of diuretic or a diuretic dosage rate provided to the patient, wherein adjusting operation of the pump is based on the obtained amount of diuretic or diuretic dosage rate.
16. The method of claim 14 , further comprising causing a diuretic to be provided to the patient at a diuretic dosage rate.
17. The method of claim 16 , wherein causing the hydration fluid to be provided occurs after causing the diuretic to be provided to the patient at the diuretic dosage rate.
18. The method of claim 14 , further comprising:
determining that the obtained urine output rate is below a threshold rate; and
providing an indication that the urine output rate is below the threshold rate.
19. The method of claim 14 , further comprising obtaining an actual net fluid loss rate, wherein adjusting operation of the pump to increase the hydration fluid rate is based on a difference between the desired net fluid loss rate and the actual net fluid loss rate.
20. The method of claim 14 , wherein the urine output rate is above a threshold rate, the method further comprising adjusting operation of the pump to decrease the hydration fluid rate.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 8, 2023
From: LEVIN, HOWARD R.; HALPERT, ANDREW; ENGELMAN, ZOAR; GELFAND, MARK
To: REPRIEVE CARDIOVASCULAR, INC.
Reel/Frame 065819/0305 →
Continuity (2)
Provisional Application
62673298
· May 18, 2018
References Cited (300)
US 3954010A
· Hilblom
· 1976
[cited by applicant]
US 4132644A
· Kolberg
· 1979
[cited by applicant]
US 4146029A
· Ellinwood, Jr.
· 1979
[cited by applicant]
US 4204957A
· Weickhardt
· 1980
[cited by applicant]
US 4216462A
· McGrath et al.
· 1980
[cited by applicant]
US 4229299A
· Savitz et al.
· 1980
[cited by applicant]
US 4261360A
· Perez
· 1981
[cited by applicant]
US 4275726A
· Schael
· 1981
[cited by applicant]
US 4291692A
· Bowman et al.
· 1981
[cited by applicant]
US 4343316A
· Jespersen
· 1982
[cited by applicant]
US 4411649A
· Kamen
· 1983
[cited by applicant]
US 4448207A
· Parrish
· 1984
[cited by applicant]
US 4449538A
· Corbitt et al.
· 1984
[cited by applicant]
US 4504263A
· Steuer et al.
· 1985
[cited by applicant]
US 4658834A
· Blankenship et al.
· 1987
[cited by applicant]
US 4712567A
· Gille et al.
· 1987
[cited by applicant]
US 4728333A
· Masse et al.
· 1988
[cited by applicant]
US 4728433A
· Buck et al.
· 1988
[cited by applicant]
US 4813925A
· Anderson, Jr. et al.
· 1989
[cited by applicant]
US 4923598A
· Schal
· 1990
[cited by applicant]
US 4994026A
· Fecondini
· 1991
[cited by applicant]
US 5098379A
· Conway et al.
· 1992
[cited by applicant]
US 5176148A
· Wiest et al.
· 1993
[cited by applicant]
US 5179862A
· Lynnworth
· 1993
[cited by applicant]
US 5207642A
· Orkin et al.
· 1993
[cited by applicant]
US 5573506A
· Vasko
· 1996
[cited by applicant]
US 5586973A
· Lemaire et al.
· 1996
[cited by applicant]
US 5709670A
· Vancaillie et al.
· 1998
[cited by applicant]
US 5722947A
· Jeppsson et al.
· 1998
[cited by applicant]
US 5769087A
· Westphal et al.
· 1998
[cited by applicant]
US 5814009A
· Wheatman
· 1998
[cited by applicant]
US 5891051A
· Han et al.
· 1999
[cited by applicant]
US 5910252A
· Truitt et al.
· 1999
[cited by applicant]
US 5916153A
· Rhea, Jr.
· 1999
[cited by applicant]
US 5916195A
· Eshel et al.
· 1999
[cited by applicant]
US 5981051A
· Motegi et al.
· 1999
[cited by applicant]
US 5984893A
· Ward
· 1999
[cited by applicant]
US 6010454A
· Arieff et al.
· 2000
[cited by applicant]
US 6171253B1
· Bullister et al.
· 2001
[cited by applicant]
US 6231551B1
· Barbut
· 2001
[cited by applicant]
US 6272930B1
· Crozafon
· 2001
[cited by applicant]
US 6514226B1
· Levin et al.
· 2003
[cited by applicant]
US 6531551B2
· Ohno et al.
· 2003
[cited by applicant]
US 6537244B2
· Paukovits et al.
· 2003
[cited by applicant]
US 6554791B1
· Cartledge et al.
· 2003
[cited by applicant]
US 6640649B1
· Paz et al.
· 2003
[cited by applicant]
US 6740072B2
· Starkweather et al.
· 2004
[cited by applicant]
US 6752779B2
· Paukovits et al.
· 2004
[cited by applicant]
US 6796960B2
· Cioanta et al.
· 2004
[cited by applicant]
US 6827702B2
· Lebel et al.
· 2004
[cited by applicant]
US 6942637B2
· Cartledge et al.
· 2005
[cited by applicant]
US 7029456B2
· Ware et al.
· 2006
[cited by applicant]
US 7044002B2
· Ericson et al.
· 2006
[cited by applicant]
US 7137964B2
· Flaherty
· 2006
[cited by applicant]
US 7278983B2
· Ireland et al.
· 2007
[cited by applicant]
US 7727222B2
· Da Silva
· 2010
[cited by applicant]
US 7736354B2
· Gelfand
· 2010
[cited by applicant]
US 7739921B1
· Babcock
· 2010
[cited by applicant]
US 7758562B2
· Gelfand
· 2010
[cited by applicant]
US 7758563B2
· Gelfand
· 2010
[cited by applicant]
US 7837667B2
· Gelfand
· 2010
[cited by applicant]
US 8007460B2
· Gelfand
· 2011
[cited by applicant]
US 8075513B2
· Rudko et al.
· 2011
[cited by applicant]
US 8233957B2
· Merz et al.
· 2012
[cited by applicant]
US 8444623B2
· Gelfand
· 2013
[cited by applicant]
US 8556846B2
· O'Mahony et al.
· 2013
[cited by applicant]
US 8714030B1
· Liu
· 2014
[cited by applicant]
US 9526833B2
· Gelfand et al.
· 2016
[cited by applicant]
US 20010029340A1
· Mault et al.
· 2001
[cited by applicant]
US 20020025597A1
· Matsuda
· 2002
[cited by applicant]
US 20020072647A1
· Schock et al.
· 2002
[cited by applicant]
US 20020107536A1
· Hussein
· 2002
[cited by applicant]
US 20020161314A1
· Sarajarvi
· 2002
[cited by applicant]
US 20030040700A1
· Hickle
· 2003
[cited by applicant]
US 20030048185A1
· Citrenbaum et al.
· 2003
[cited by applicant]
US 20030048432A1
· Jeng et al.
· 2003
[cited by applicant]
US 20030114786A1
· Hiller et al.
· 2003
[cited by applicant]
US 20040081585A1
· Reid
· 2004
[cited by applicant]
US 20040122353A1
· Shahmirian et al.
· 2004
[cited by applicant]
US 20040133187A1
· Hickle
· 2004
[cited by applicant]
US 20040163655A1
· Gelfand et al.
· 2004
[cited by applicant]
US 20040167415A1
· Gelfand
· 2004
[cited by applicant]
US 20060064053A1
· Bollish et al.
· 2006
[cited by applicant]
US 20060100743A1
· Townsend et al.
· 2006
[cited by applicant]
US 20070088333A1
· Levin et al.
· 2007
[cited by applicant]
US 20080027409A1
· Rudko et al.
· 2008
[cited by applicant]
US 20080051764A1
· Dent et al.
· 2008
[cited by applicant]
US 20090062730A1
· Woo
· 2009
[cited by examiner]
US 20100280443A1
· Gelfand et al.
· 2010
[cited by applicant]
US 20100280444A1
· Gelfand et al.
· 2010
[cited by applicant]
US 20120259308A1
· Gelfand
· 2012
[cited by applicant]
US 20130104667A1
· Koyano
· 2013
[cited by applicant]
US 20130261412A1
· Reed
· 2013
[cited by applicant]
US 20130274705A1
· Burnes et al.
· 2013
[cited by applicant]
US 20140031787A1
· Burnes et al.
· 2014
[cited by applicant]
US 20140073973A1
· Sexton
· 2014
[cited by applicant]
US 20140228755A1
· Darrah et al.
· 2014
[cited by applicant]
US 20150258277A1
· Halpert
· 2015
[cited by examiner]
US 20160051176A1
· Ramos et al.
· 2016
[cited by applicant]
US 20170016755A1
· Boussange et al.
· 2017
[cited by applicant]
US 20180071455A9
· Halpert
· 2018
[cited by applicant]
US 20180280620A1
· Reichthalhammer
· 2018
[cited by applicant]
US 20190038833A1
· Pirazzoli et al.
· 2019
[cited by applicant]
US 20190262532A1
· Oh et al.
· 2019
[cited by applicant]
US 20200360604A1
· Kolko et al.
· 2020
[cited by applicant]
US 20210077007A1
· Jouret et al.
· 2021
[cited by applicant]
US 20210085853A1
· Chen et al.
· 2021
[cited by applicant]
US 20210260306A1
· Gravenstein et al.
· 2021
[cited by applicant]
US 20220152302A1
· Halpert
· 2022
[cited by applicant]
US 20230414871A1
· Halpert
· 2023
[cited by applicant]
EP 0258690
· 1998
[cited by applicant]
EP 1986007
· 2008
[cited by applicant]
EP 3278833
· 2018
[cited by applicant]
EP 4108171
· 2022
[cited by applicant]
GB 2560580
· 2018
[cited by applicant]
JP 2008110150
· 2008
[cited by applicant]
JP 2011520549
· 2011
[cited by applicant]
JP A2011520549
· 2011
[cited by applicant]
JP A2017536857
· 2017
[cited by applicant]
KR 1020220035738
· 2022
[cited by applicant]
WO WO1996016685
· 1996
[cited by applicant]
WO WO1996028209
· 1996
[cited by applicant]
WO WO1997016220
· 1997
[cited by applicant]
WO WO1999006087
· 1999
[cited by applicant]
WO WO2005102441
· 2005
[cited by applicant]
WO WO2006041496
· 2006
[cited by applicant]
WO WO2009029899
· 2009
[cited by applicant]
WO WO2013154783
· 2013
[cited by applicant]
WO WO2014022422
· 2014
[cited by applicant]
WO WO2015142617
· 2015
[cited by applicant]
WO WO2016103256
· 2016
[cited by applicant]
WO WO2018114794
· 2018
[cited by applicant]
WO WO2019222485
· 2019
[cited by applicant]
WO WO2020033752
· 2020
[cited by applicant]
WO WO2022219578
· 2022
[cited by applicant]
PCT Search Report and Written Opinion, Appl. No. PCT/US19/32641, dated Mar. 31, 2020, 22 pages.
[cited by applicant]
Japanese Office Action mailed Jun. 19, 2023 (with English Translation); Japanese Patent Application No. 2021-514940; 6 pages.
[cited by applicant]
Chinese Office Action mailed Sep. 8, 2023 (with English Translation); Chinese Patent Application No. 201980048123.3; 28 pages.
[cited by applicant]
U.S. Appl. No. 16/544,975, filed Aug. 20, 2019, Levin.
[cited by applicant]
U.S. Appl. No. 18/434,540, filed Feb. 6, 2024, Halpert.
[cited by applicant]
U.S. Appl. No. 16/595,182, filed Mar. 4, 2024, Levin.
[cited by applicant]
U.S. Appl. No. 18/637,340, filed Apr. 16, 2024, Conley et al..
[cited by applicant]
U.S. Appl. No. 18/641,241, filed Apr. 19, 2024, Da Silva.
[cited by applicant]
“2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure—Web Addenda,” European Heart Journal, 17 pages.
[cited by applicant]
Abraham Otero, “A New Device to Automate the Monitoring of Critical Patients' Urine Output”, Hindawi Publishing Corp, BioMed Research Int'l, vol. 2014, Article ID 587593, 8 pages.
[cited by applicant]
Adams et al., “Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline,” Journal of Cardiac Failure, vol. 12, No. 1, 2006, pp. 10-38.
[cited by applicant]
Adaptec Medical Devices, “Ongoing Access To Real-Time And Accurate Monitoring Of Urine Output Could Improve Management Of Critically Ill Patients,” Clinical Literature Review, (2016) 8 pages.
[cited by applicant]
Alison Shepherd, “Measuring and Managing Fluid Balance”, Nursing Times, vol. 107, No. 28, pp. 12-16 (Jul. 19, 2011) 5 pages.
[cited by applicant]
Allen et al., “Continuous Versus Bolus Dosing of Furosemide for Patients Hospitalized for Heart Failure,” American Journal of Cardiology, 105(12): 1794-1794, 2010.
[cited by applicant]
Antonio Tricoli, “Miniaturized Bio-and Chemical-Sensors for Point-of-Care Monitoring of Chronic Kidney Diseases,” Sensors 2018, 18, 942; (Mar. 22, 2018) 18 pages.
[cited by applicant]
Baliga, “Diuretic Therapy for Heart Failure Patients,” American College of Cardiology, 75:1178-1195, 2020.
[cited by applicant]
Barbara Lara, “Accurate Monitoring Of Intravascular Fluid Volume: A Novel Application Of Intrathoracic Impedance Measures For The Guidance Of vol. Reduction Therapy,” IJC Heart & Vasculature, 8 (2015) pp. 47-51, 5pages.
[cited by applicant]
Bell et al., “Risk of Postoperative Acute Kidney Injury in Patients Undergoing Orthopaedic Surgery—Development and Validation of Risk score and Effect of Acute Kidney Injury on Survival: Observational Cohort Study,” BMJ…
[cited by applicant]
Bouman et al., “Red Blood Cell Transfusion and Furosemide in Cardiac Surgery: Friend and Foe?” The Netherlands Journal of Medicine, Dec. 2012, vol. 70, No. 10, 3 pages.
[cited by applicant]
Brater, “Diuretic Therapy,” New England Journal of Medicine, 339:387-395, 1998.
[cited by applicant]
Cosgrove III et al., “Automated Control Postoperative Hypertension: A Prospective Randomized Multicenter Study,” 1989 by The Society of Thoracic Surgeons, 6 pages.
[cited by applicant]
David Farcy, “Review: Pitfalls in Using Central Venous Pressure as a Marker of Fluid Responsiveness,” Emergency Medicine. Jan. 2016;48(1): 18-28, 15 pages.
[cited by applicant]
Ellison et al., “Diuretic Treatment in Heart Failure,” New England Journal of Medicine, 377:1964-1975, 2017.
[cited by applicant]
Farkas, “Deresuscitation: Dominating the Diuresis,” The Internet Book of Critical Care, 43 p. 2020.
[cited by applicant]
Furutani et al., “An Automatic Control System of the Blood Pressure of Patients Under Surgical Operation,” International Journal of Control, Automation, and Systems, vol. 2, No. 1, Mar. 2004, pp. 39-54.
[cited by applicant]
Gheorghiade et al., “Current Medical Therapy for Advanced Heart Failure,” American Heart Journal, Jun. 1998, pp. S231-S248.
[cited by applicant]
Goren et al., “Perioperative Acute Kidney Injury,” British Journal of Anaesthesia, 2015, 12 pages.
[cited by applicant]
Hasselblad et al., “Relation Between Dose of Loop Diuretics and Outcomes in a Heart Failure Population: Results of the ESCAPE Trial”, European Journal of Heart Failure, 9(10):1064-1069, 2007.
[cited by applicant]
Kambiz Kalantari, “Assessment Of Intravascular Volume Status and Volume Responsiveness In Critically Ill Patients,” Kidney International (2013) 83, 1017-1028 (Jan. 9, 2013) 12 pages.
[cited by applicant]
Kolh, “Renal Insufficiency After Cardiac Surgery: A Challenging Clinical Problem,” European Heart Journal, 2009, pp. 1824-1827.
[cited by applicant]
Kui Jin et al., “Intensive Monitoring of Urine Output Is Associated With Increased Detection of Acute Kidney Injury and Improved Outcomes,” Chest Journal—Original Research Critical Care, 152#5, pp. 972-979 (Nov. 2017) 8…
[cited by applicant]
Lassnigg et al., “Lack of Renoprotective Effects of Dopamine and Furosemide During Cardiac Surgery,” J. Am Soc Nephrol, 2000, pp. 97-104.
[cited by applicant]
Lenihan et al., “Trends in Acute Kidney Injury, Associated Use of Dialysis and Mortality After Cardiac Surgery, 1999 to 2008,” Ann Thorac Surg. 2013, 17 pages.
[cited by applicant]
Marenzi et al., “Prevention of Contrast Nephropathy by Furosemide With Matched Hydration,” JACC: Cardiovascular Interventions, 5(1):90-97, 2011.
[cited by applicant]
Mayo Clinic, “Creatinine Test”, Mayo Foundation for Medical Education and Research (MFMER) (downloaded Aug. 16, 2018).
[cited by applicant]
Meersch et al., “Perioperative Acute Kidney Injury: An Under-Recognized Problem,” vol. 125, No. 4, www.anesthesia-analgesia.org, Oct. 2017, pp. 1223-1232.
[cited by applicant]
Mendeley et al., “Furosemide”, Science Direct, 5 pages, 2016.
[cited by applicant]
Oh et al., “Loop Diuretics in Clinical Practice,” Review: Electrolyte Blood Press, 13(1): 5 pages, 2015.
[cited by applicant]
Olivero et al., “Acute Kidney Injury After Cardiovascular Surgery: An Overview,” debakeyheartcenter.com/journal, 2012, pp. 31-36.
[cited by applicant]
Palazzuli et al. “Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial,” Critical Care 18, 2014.
[cited by applicant]
Phillips et al., “Measurement of sodium ion concentration in undiluted urine with cation-selective polymeric membrane electrodes after the removal of interfering compounds”, Talanta, Elsevier, Amsterdam, NL, vol. 74, No…
[cited by applicant]
Prandota et al., “Pharmacokinetics and metabolism of furosemide in man,” European Journal of Drug Metabolism and Pharmcokinetics, 1(4): 5 pages, 1976.
[cited by applicant]
Rosenberg et al., “Combination Therapy with Metolazone and Loop Diuretics in Outpatients with Refactory Heart Failure: An Observational Study and Review of the Literature,” Cardiovascular Drugs and Therapy, Kluwer Acade…
[cited by applicant]
Rui Geng et al., “Identification of Modifiable Risk Factors for Acute Kidney Injury After Coronary Artery Bypass Graft Surgery in an Asian Population,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2014, pp. …
[cited by applicant]
Se Won Oh et al., “Loop Diuretics In Clinical Practice”, Electrolytes & Blood Pressure, www.ncbi.nlm.nih.gov/pmc/articles/PMC4520883, printed Mar. 25, 2019, 6 pages.
[cited by applicant]
Stickler et al., “A Sensor To Detect the Early Stages in the Development of Crystalline Proteus mirabilis Biofilm on Indwelling Bladder Catheters”, Journal of Clinical Microbiology, Apr. 2006, p. 1540-1542.
[cited by applicant]
Teixeira et al., “Fluid Balance and Urine vol. are Independent Predictors of Mortality in Acute Kidney Injury”, Critical Care 17:R14 (2013) 11 pages.
[cited by applicant]
Testani et al., “Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients with Heart Failure,” Circulation; Heart Failure, vol. 9. No. 1, 2016, 32 pages.
[cited by applicant]
Thakar, “Perioperative Acute Kidney Injury,” Advances in Chronic Kidney Disease, vol. 20, No. 1, 2013, pp. 67-75.
[cited by applicant]
Unknown Author, “Furosemide Drug Summary,” Prescriber's Digital Reference, pp. 1-31, 2016.
[cited by applicant]
Vellinga et al., “Identification of Modifiable Risk Factors for Acute Kidney Injury After Cardiac Surgery,” The Netherlands Journal of Medicine, vol. 70, No. 10, Dec. 2012, pp. 450-454.
[cited by applicant]
Vivane Conradds, “Sensitivity And Positive Predictive Value Of Implantable Intrathoracic Impedance Monitoring As A Predictor Of Heart Failure Hospitalizations: The SENSE-HF Trial,” European Heart Journal (2011) 32, 2266…
[cited by applicant]
Yeh et al., “Goal-directed diuresis: A case-control study of continuous furosemide infusion in critically ill trauma patients”, The Journal of Emergencies, Trauma, and Shock, 8(1): 34-38, 2015.
[cited by applicant]
European Office Action and Extended Search Report for European Patent Application No. 19790336.2, Applicant: Reprieve Cardiovascular, Inc., mailed Dec. 18, 2023, 10 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2005/008948 dated Oct. 3, 2006, 3 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/021791 dated May 8, 2008, 7 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/U20S07/009685 dated Jul. 18, 2008, 10 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/009684 dated Jul. 21, 2008, 7 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2008/007845 dated Sep. 17, 2008, 5 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2008/007841 dated Sep. 18, 2008 4 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2007/009683 dated Nov. 24, 2008, 6 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2009/002739 dated Jun. 19, 2009, 4 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2010/000137 dated Mar. 16, 2010, 8 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2015/020196, dated Jun. 12, 2015, 5 pages.
[cited by applicant]
Bart et al., “Ultrafiltration in Decompensated Heart Failure With Cardiorenal Syndrome”, The New England Journal of Medicine, Dec. 13, 2012, 9 pages, Massachusetts Medical Society.
[cited by applicant]
Brezis et al., Hypoxia of the Renal Medulla—Its Implications for Disease, New England Journal of Medicine, vol. 322, No. 10, Mar. 9, 1995, 9 pages.
[cited by applicant]
Briguori et al., “Renal Insufficiency After Contrast Media Administration Trial II (Remedial II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury”, Circulation, Journal of the American H…
[cited by applicant]
Dorval et al., “Feasibility Study of the RenalGuard™ Balanced Hydration System: A Novel Strategy for the Prevention of Contrast-Induced Nephropathy in High Risk Patients”, International Journal of Cardiology, 2011, 5 pa…
[cited by applicant]
Edelson et al., Pharmacokinetics of lohexol, a New Nonionic Radiocontrast Agent, in Humans, Journal of Pharmaceutical Sciences, vol. 73, No. 7, Jul. 1984, 3 pages.
[cited by applicant]
Felker et al., “Diuretic Strategies in Patients With Acute Decompensated Heart Failure”, The New England Journal of Medicine, Mar. 3, 2011, vol. 364, No. 9, 9 pages.
[cited by applicant]
Gloor, James M. and Vincente E. Torres, Reflux and Obstructive Nephropathy, Atlas of Diseases of the Kidney, on-line edition, vol. Two, Section I, Ch. 8, pp. 8.1-8.25, 1999, 27 pages.
[cited by applicant]
Hvistendahl et al., Renal Hemodynamic Response to Gradated Ureter Obstruction in the Pig, Nephron 1996, 74:168-74, 7 pages.
[cited by applicant]
Lelarge et al., Acute Unilateral Renal Failure and Contralateral Ureteral Obstruction, American Journal of Kidney Diseases, vol. XX, No. 3, Sep. 1992, 3 pages.
[cited by applicant]
Levin et al. High-volume diuresis with matched maintenance of intravascular volume may prevent contrast-induced nephropathy in post-transplant patients with moderate-severe baseline renal impairment, Cardiovascular Reva…
[cited by applicant]
Lloyd-Jones et al., “Heart Disease and Stroke Statistics—2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee”, Circulation, Journal of the American Heart Ass…
[cited by applicant]
Marenzi et al.. “Prevention of Contrast Nephropathy by Furosemide With matched Hydration. The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) T…
[cited by applicant]
Mawer et al., “Value of Forced Diuresis in Acute Barbiturate Poisoning”, Jun. 29, 1968, British Medical Journal, 2, 4 pages.
[cited by applicant]
Paterna et al., “Changes in Brain Natriuretic Peptide Levels and Bioelectrical Impedance Measurements After Treatment With High-Dose Furosemide and Hypertonic Saline Solution Versus High-Dose Furosemide Alone in Refract…
[cited by applicant]
Pederson et al., Renal Water and Sodium Handling During Gradated Unilateral Ureter Obstruction, Scand J. Urol Nephrol, 2002, 36:163-72, 11 pages.
[cited by applicant]
Rihal et al., Incidence and Prognostic Importance of Acute Renal Failure After Percutaneous Coronary Intervention, Circulation, May 14, 2002, 6 pages.
[cited by applicant]
Rosamilia et al., Electromotive Drug Administration of Lidocaine and Dexamethasone Followed by Cystodistension in Women with Interstitial Cystitis, International Urogyecologyl Journal, Pelvic Floor Dysfunction 1997; 8: …
[cited by applicant]
S215 Ultra Low Profile Single Point Load Cell-Strain Guage Sensors and Load Cells, Ultra-Low Profile Single Point Load Cell-S215, http://smdsensors.com/detail_pgs/s215.htm 2005, 3 pages.
[cited by applicant]
Solomon et al., Effects of Saline, Mannitol, and Furosemide on Acute Decreases in Renal Function Induced by Radiocontrast Agents, The New England Journal of Medicine, vol. 331: 1416-1420, Nov. 24, 1994, No. 21, 5 pages.
[cited by applicant]
Stevens, Melissa A., Md et al., A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy, Results of the P.R.I.N.C.E. Study, Journal of American College of Cardiology, vol.…
[cited by applicant]
Stevenson et al., “Editorial Comment, Torrent or Torment From the Tubules?”, Challenge of the Cardiorenal Connections, Journal of the American College of Cardiology, vol. 45, No. 12, 2005, 4 pages.
[cited by applicant]
Wakelkamp et al., The influence of drug input rate on the development of tolerance to frusemide, Br. J. Clin. Pharmacol 1998, 46:479-487, 9 pages.
[cited by applicant]
Weinstein et al., Potential deleterious Effect of Furosmide in Radiocontrast Nephropathy, Department of Medicine, Hadassah Univeristy Hospital, Mount Scopus, Jerusalem, Israel, Nephron 1992, 62: 413-415, pages.
[cited by applicant]
Doty et al., Effect of Increased Renal Venous Pressure on Renal Function, The Journal of Trauma: Injury, Infection and Critical Care, vol. 47, No. 6, Dec. 1999, 4 pages.
[cited by applicant]
Heyman et al., Pathophysiology of Radiocontrast Nephropathy: A Role for Medullary Hypoxia, Investigative Radiology, vol. 34, No. 11, Nov. 1999, 7 pages.
[cited by applicant]